Genetic variations in drug-induced liver injury (DILI): resolving the puzzle [PDF]
Frontiers in Genetics, 2012 Despite stringent requirements for drug development imposed by regulatory agencies, drug-induced liver injury (DILI) is an increasing health problem and a significant cause for failure to approve drugs, market withdrawal of commercialized medications, and adoption of regulatory measures.
Camilla Stephens +2 more
openalex +6 more sources
Machine-Learning Prediction of Oral Drug-Induced Liver Injury (DILI) via Multiple Features and Endpoints. [PDF]
Biomed Res Int, 2020 Liu X +5 more
europepmc +3 more sources
Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. [PDF]
Ann Transl Med, 2021 Clinical features of idiosyncratic drug induced liver injury (DILI) are well described in cases that have been assessed for causality using the Roussel Uclaf Causality Assessment Method (RUCAM), but our understanding of the mechanistic steps leading to injury is fragmentary.
Teschke R, Uetrecht J.
europepmc +5 more sources
Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure. [PDF]
Biol Direct, 2021 Abstract Background: Drug-induced liver injury (DILI) is a major safety concern characterized by a complex and diverse pathogenesis. In order to identify DILI early in drug development, a better understanding of the injury and models with better predictivity are urgently needed.
Liu A +7 more
europepmc +8 more sources
Mortality associated with drug-induced liver injury (DILI). [PDF]
Transl Gastroenterol Hepatol, 2017 Idiosyncratic drug-induced liver injury (DILI) is an important cause of liver failure and liver injury leading to transplantation, although in most cases self-remitting when administration of the offending drug is stopped (1-3). In rare cases DILI can lead to a persistent/chronic form of injury (4).
Björnsson ES, Björnsson HK.
europepmc +5 more sources
Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis. [PDF]
Int J Mol SciMoreno-Torres M +4 more
europepmc +3 more sources
Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report. [PDF]
Cureus, 2022 Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI).
Zachou M +4 more
europepmc +3 more sources
Dyslipidemia is a Risk Factor for the Incidence and Severity of Drug-Induced Liver Injury (DILI): A Retrospective Population-Based Study in China. [PDF]
Med Sci Monit, 2019 Li X, Wang L, Li D, Niu J, Gao P.
europepmc +3 more sources
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. [PDF]
PLoS One, 2017 Peta V +24 more
europepmc +3 more sources
Drug-Induced Liver Injury in Tuberculosis: Mechanisms of Development and Diagnostic Methods
Juvenis Scientia, 2023 The review article discusses modern aspects of drug-induced liver injury (DILI) in patients with tuberculosis who are receiving etiotropic therapy. The main mechanisms of DILI, including toxic and idiosyncratic types, are described, as well as their ...
D. S. Sukhanov +3 more
doaj +1 more source